Datos de interés

• Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results - MarketWatch (press release)
  

  Jazz Pharmaceuticals Announces First Quarter 2012 Financial ResultsMarketWatch (press release)Psychiatry Products: Net sales of the company's psychiatry products, including once-daily Luvox CR® (fluvoxamine maleate), FazaClo HD and FazaClo LD were $17.

• Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results - PR Newswire (press release)
  

  Jazz Pharmaceuticals Announces First Quarter 2012 Financial ResultsPR Newswire (press release)Psychiatry Products: Net sales of the company's psychiatry products, including once-daily Luvox CR® (fluvoxamine maleate), FazaClo HD and FazaClo LD were $17.

• Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma - MarketWatch (press release)
  

  Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA PharmaMarketWatch (press release)The company's marketed products in these areas include: Xyrem® (sodium oxybate), Prialt® (ziconotide intrathecal infusion), FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine maleate) and Elestrin® (estradiol gel 0.

• Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference ... - MarketWatch (press release)
  

  Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference .

• Jazzed up for M&A, VCs Get a Return - Private Equity Hub (press release)
  

  Jazzed up for M&A, VCs Get a ReturnPrivate Equity Hub (press release)The company's marketed products in these areas include: Xyrem® (sodium oxybate), Prialt® (ziconotide intrathecal infusion), FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine maleate) and Elestrin® (estradiol gel 0.